Pharma intelligence in minutes,
not meetings.
FDA approvals, trials, patents, pipelines — into clear decisions, fast.
Try:
·
·
·
·
·
8,600+ drugs · 150,000+ trials · 1,300+ patent landscapes · Updated weekly.
Start 30-day Pro trial — free →
No credit card required
Questions TheraRadar answers
Tap any question to jump straight to the data.
Recent FDA Approvals
Updated Jul 17, 2026
Upcoming FDA Decisions
Full calendarRivoceranib + camrelizumab
Elevar Therapeutics, Inc.
2026-07-23
5d away
Rivoceranib + camrelizumab
Elevar Therapeutics, Inc.
July 23, 2026
5d away
Tavapadon
AbbVie Inc.
2026-07-26
8d away
Latest brief The Disease That Wasn't Rare After All
All briefs → Pro tools
Pre-built analyses. The slow research is already done.
🧬
Competitive heatmaps
90+ interactive grids — indication landscapes (company × mechanism), company portfolios, and MOA platforms. Click any cell to drill into the trials.
⚖️
Compare two companies
Head-to-head comparison of any two company portfolios — pipeline, approvals, and revenue side by side.
🔬
Clinical Trials Explorer
Search and filter 150,000+ trials by drug, sponsor, phase, and condition.
📉
Patent Cliff with revenue arcs
Humira -73%, Revlimid -81%, Stelara -43% — actual SEC revenue declines, not Medicare proxies.
Data sources: FDA Drugs@FDA, ClinicalTrials.gov, Orange Book, SEC EDGAR.
Data updated: Jul 17, 2026